Genmab (GMAB)
(Delayed Data from NSDQ)
$30.22 USD
+0.69 (2.34%)
Updated May 15, 2024 04:00 PM ET
After-Market: $30.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GMAB 30.22 +0.69(2.34%)
Will GMAB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMAB
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 17th
GMAB or TECH: Which Is the Better Value Stock Right Now?
HRMY or GMAB: Which Is the Better Value Stock Right Now?
Other News for GMAB
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
Genmab to present new, updated results from abstracts evaluating epcoritamab
Novo Nordisk mim8 data near Jefferies' 'best' case scenario
Genmab Advances Share Buy-back Program
Genmab A/S Details Capital and Corporate Structure